A new vaccine for covid-19 is being developed Texas Scientists have used decades-old traditional methods to make production and distribution cheaper and for the countries most affected by the epidemic, and where newer variants are likely to emerge due to lower vaccination rates.
Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine. The team, led by Peter Hotage and Maria Bottazzi, has been developing vaccine prototypes for SARS and MERS since 2011, which they rebuilt to create a new covid vaccine called Corbevax. , Or “The World’s Covid-19 Vaccine”.
Although More than 60 Other vaccines are being developed using the same technology, Botazzi said, adding that their vaccine is unique because they do not intend to patent it, allowing anyone with the ability to reproduce it.
“Anyone who can make a hepatitis B vaccine or produce microbial-based proteins, such as bacteria or yeast, can mimic what we do,” Bottazzi said.
The patent war for the mRNA vaccine has recently erupted. Moderna and the National Institutes of Health are at loggerheads over who should be credited with inventing the covid-19 vaccine. 73 million Americans. If Moderna is found to have infringed on a federal government’s patent, he may be forced to pay more than that. 1 billion.
At the same time, activists have called on Pfizer and Moderna to share their vaccine production techniques and knowledge, to take them into combat. World Trade Organization. In low-income countries, with limited vaccine research and production facilities, only one in nine people have been vaccinated. World Health Organization. America has done it 67% fully vaccinated The third vaccine was given to more than a third of the population.
Corbevax’s clinical trial data have not yet been released due to lack of resources, but Texas Children’s Hospital says the vaccine is 90% effective against the original Covid-19 and more than 80% effective against the Delta variant. The effectiveness of the vaccine against the Omicron variant is currently being tested.
The process of creating the vaccine involves the use of yeast – from which hepatitis B vaccines are produced.
Currently available in the US, Moderna, Pfizer and Johnson & Johnson vaccines use different technologies or vaccine “platforms”. Moderna and Pfizer use Messenger RNA (mRNA) technology. The platform introduces the Covid-19 immune system by providing instructions on how to produce the most recognizable feature of the spike proteins that coat its surface. This helps the immune system to detect and fight the virus later, if a person comes in contact with it. Johnson & Johnson’s vaccine introduces immune cells into spike proteins through a technique called the otherwise harmless cold virus, the viral vector.
The Corbevax vaccine uses a platform called recombinant protein sub-unit technology, which puts real pieces of the covid-19 spike protein into yeast cells. Yeast cells then replicate important proteins and the proteins are introduced into the immune system.
“We make proteins, directly and synthetically, in the laboratory using yeast systems,” Bottazzi explained. “We ask yeast to make a protein that looks like a protein made by a virus. We then immune to the protein and the body processes the protein and presents it to the immune system. Therefore, you should not ask your body to make any major manipulation of the coding. “
Importantly, the Corbevax vaccine requires only a standard refrigerator, unlike the Pfizer vaccine, which requires ultra-cold storage in transit.
Indian pharmaceutical company Biological E, which has a long association with Bottazzi’s team to produce hepatitis B vaccines, has produced 150 million doses of the new carbevax vaccine and will soon be able to produce 100 million doses per month.
After being ignored by government agencies for funding, Bottazzi said the developers of Kerbevax relied on philanthropic donations to get them to the finish line. The Texas Children’s Hospital Center for Vaccine Development is an educational and scientific institution in nature, but Bottazzi said the developing carbex had forced them to expand their resources to gain visibility as serious candidates for covid vaccine development.
“We’re learning how to do things on our own, enabling regulators, good quality, good reproduction, good record-keeping … we mimic like a small biotech or production company,” she said. “Every technology has its advantages and disadvantages. No one claims to be a super-duper, just the solution. All [vaccines] Is part of the solution. But when you have such a gravitational situation around the world, you don’t choose the solution and don’t solve it – you try to use all the solutions, “Botazzi said.
Bottazzi said the reason he and his team did not patent the vaccine was because his team shared a common philosophy of humanism and cooperated with the wider scientific community.
“We want to do better in the world. It was the right thing to do and we have to do it morally. We didn’t even blink. We didn’t think, ‘How can we take advantage of this?’ You now see how unequal the world is for many like us and how ‘what will happen to me?’ We would have been more focused on how we could have helped from the beginning without thinking. Basically these variants didn’t show up. “
Bottazzi hopes his move will encourage others to follow suit and create affordable and accessible vaccines for other diseases and viruses, such as hookworm.
“We need to break these paradigms that it is driven solely by economic impact factors or the return on economic investment. We need to look at the return to public health.”